
• Reported GAAP EPS of $0.69 up 76.92% YoY • Reported revenue of $1.26B up 13.12% YoY • Dexcom reiterates fiscal year 2026 guidance, targeting Revenue of $5.16-$5.25 billion, Non-GAAP Gross Profit Margin of 63-64%, Operating Margin of 22-23%, and Adjusted EBITDA Margin of 30-31%.
Bullish
Dexcom achieved strong Q4 and full-year 2025 revenue growth, with significant increases in operating income. Product innovation and expanded market access through new CGM systems and regional coverage drove performance.
Bearish
Dexcom faced ongoing intellectual property litigation costs and business transition expenses, impacting non-GAAP measures. Total current assets decreased while current liabilities increased, indicating a shift in working capital.